Thermo Fisher Scientific Stock (NYSE: TMO)

Thermo Fisher Scientific (NYSE:TMO) Stock, Quote.Headers.trade-ideas

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

Biotech

Earnings

Earnings Beats

Large Cap

News

Markets

Analyst Ratings

Trading Ideas

General

Thermo Fisher Scientific Inc. (NYSE: TMO) is gaining investors&#39; confidence due to its impressive partnerships. Of late, the company has launched a slew of products to enhance its portfolio.

Reasons to Retain Thermo Fisher in Your Portfolio Now

cancer

Health Care

Legal

Media

RARE

VTRS

Henrietta Lacks&#39; family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.

Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs

lockheed shutter

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

11 large-cap stocks saw significant gains in the last week, driven by positive earnings and guidance updates. Check if they&#39;re in your portfolio.

Universal Health Services &amp; Lockheed Martin Were Among Top 11 Large Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

Trimol Group Inc

JP Morgan analyst Rachel Vatnsdal maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and raises the price target from $650 to $670.

Price Target

JP Morgan Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $670

Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and raises the price target from $615 to $680.

Stifel Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $680

RBC Capital analyst Conor McNamara reiterates Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and maintains $767 price target.

Reiteration

RBC Capital Reiterates Outperform on Thermo Fisher Scientific, Maintains $767 Price Target

Morgan Stanley analyst Tejas Savant maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and raises the price target from $655 to $680.

Morgan Stanley Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $680

At today's event, Thermo Fisher Scientific highlighted:
<ul>
<li>Incredibly well-positioned industry leadership, with leading businesses that enable our customers' success
<ul>
<li>Our industry-leading businesses are benefited by total company scale and capabilities. &nbsp;</li>
</ul>
</li>
<li>Attractive end markets that are fueled by enduring long-term trends
<ul>
<li>Thermo Fisher is the industry leader serving an attractive $235 billion market with long-term market growth of 4% to 6%. &nbsp;</li>
</ul>
</li>
<li>Proven growth strategy drives share gain
<ul>
<li>High-impact innovation: enabling major scientific breakthroughs.</li>
<li>The trusted partner to our customers: enabling customer success with an excellent reputation and credibility built over a long period of time.</li>
<li>Unparalleled commercial engine: commercial advantage through deep engagement with customers wherever they are. &nbsp;</li>
</ul>
</li>
<li>Practical Process Improvement Business System (PPI) enables outstanding execution
<ul>
<li>PPI is the core of Thermo Fisher's culture, with a focus on continuous improvement that drives quality, productivity and customer allegiance and engages every colleague to find a better way, every day.</li>
<li>PPI delivers competitive advantage and drives differentiated financial performance. &nbsp;</li>
</ul>
</li>
<li>Delivering differentiated value creation for all our stakeholders
<ul>
<li>Industry leading businesses have a long-standing track record of value creation.</li>
<li>Disciplined approach to capital deployment, which consists of strategic M&amp;A and returning capital to shareholders, enables us to better serve our customers and create tremendous value for our shareholders.</li>
<li>Mission-led comprehensive CSR strategy delivers competitive advantage through our innovations for a cleaner planet, investments in colleagues and communities and our focus on impact and accountability. More details can be found in the most recent <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcorporate.thermofisher.com%2Fcontent%2Fdam%2Ftfcorpsite%2Fdocuments%2Fcorporate-social-responsibility%2Fannual-reports%2F2023-CSR-Report.pdf&amp;esheet=54124207&amp;newsitemid=20240919299545&amp;lan=en-US&amp;anchor=CSR+Report&amp;index=1&amp;md5=043c86c39168bf774d5a27615ad0617f">CSR Report</a>. &nbsp;</li>
</ul>
</li>
<li>Outstanding track record of financial performance and an excellent long-term outlook
<ul>
<li>Thermo Fisher's proven growth strategy drives share gain, and its capital deployment approach creates tremendous value, positioning the company to deliver organic revenue growth of 7% to 9% and mid-teens adjusted EPS growth over the long term.</li>
</ul>
</li>
</ul>

Thermo Fisher Scientific Hosts 2024 Investor Day, Showcasing Industry-Leading Businesses, Proven Growth Strategy, And Strong Long-Term Financial Outlook

In the latest quarter, 9 analysts provided ratings for Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $641.56, along with a high estimate of $675.00 and a low estimate of $600.00. Marking an increase of 2.49%, the current average surpasses the previous average price target of $626.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726491610_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Thermo Fisher Scientific among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$675.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$670.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$658.00</td>
<td>$648.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$660.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$664.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$615.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$632.00</td>
<td>$620.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$600.00</td>
<td>$615.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$600.00</td>
<td>$615.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Thermo Fisher Scientific. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Thermo Fisher Scientific's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Thermo Fisher Scientific's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Thermo Fisher Scientific analyst ratings.</a>
<h2>About Thermo Fisher Scientific</h2>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Financial Insights: Thermo Fisher Scientific</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Challenges: Thermo Fisher Scientific's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -1.37%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Thermo Fisher Scientific's ROE stands out, surpassing industry averages. With an impressive ROE of 3.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Thermo Fisher Scientific's ROA excels beyond industry benchmarks, reaching 1.58%. This signifies efficient management of assets and strong financial health.
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.75, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Thermo Fisher Scientific Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

B of A Securities analyst Derik De Bruin maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and raises the price target from $600 to $675.

B of A Securities Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $675

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 7.46% on an annualized basis producing an average annual return of 19.03%. Currently, Thermo Fisher Scientific has a market capitalization of $236.61 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 15 years ago, it would be worth $13,025.01 today based on a price of $619.86 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725904816_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $13,000 Today

Deep-pocketed investors have adopted a bearish approach towards Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TMO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Thermo Fisher Scientific. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 2 are puts, totaling $62,734, and 6 are calls, amounting to $487,222.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $530.0 to $710.0 for Thermo Fisher Scientific during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Thermo Fisher Scientific stands at 69.25, with a total volume reaching 268.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Thermo Fisher Scientific, situated within the strike price corridor from $530.0 to $710.0, throughout the last 30 days.
<h3>Thermo Fisher Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725557565_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$96.6</td>
<td>$90.8</td>
<td>$93.0</td>
<td>$530.00</td>
<td>$167.4K</td>
<td style="text-align: right;">172</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$83.5</td>
<td>$82.0</td>
<td>$82.0</td>
<td>$550.00</td>
<td>$147.6K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$43.4</td>
<td>$41.6</td>
<td>$43.2</td>
<td>$590.00</td>
<td>$69.1K</td>
<td style="text-align: right;">59</td>
<td style="text-align: right;">37</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.1</td>
<td>$650.00</td>
<td>$37.7K</td>
<td style="text-align: right;">73</td>
<td style="text-align: right;">112</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$37.5</td>
<td>$34.8</td>
<td>$36.39</td>
<td>$710.00</td>
<td>$36.5K</td>
<td style="text-align: right;">54</td>
<td style="text-align: right;">32</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Following our analysis of the options activities associated with Thermo Fisher Scientific, we pivot to a closer look at the company's own performance.
<h3>Where Is Thermo Fisher Scientific Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 593,628, with TMO's price down by -0.01%, positioned at $611.84.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $670.0.
<ul>
<li>An analyst from Wells Fargo downgraded its action to Overweight with a price target of $670. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Thermo Fisher Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on Thermo Fisher Scientific: Analyzing the Surge in Options Activity

Wells Fargo analyst Brandon Couillard initiates coverage on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight rating and announces Price Target of $670.

Initiation

Wells Fargo Initiates Coverage On Thermo Fisher Scientific with Overweight Rating, Announces Price Target of $670

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 6.77% on an annualized basis producing an average annual return of 17.54%. Currently, Thermo Fisher Scientific has a market capitalization of $230.65 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 10 years ago, it would be worth $500.57 today based on a price of $604.24 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724349623_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today

Thermo Fisher Scientific Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmo#NYSE">TMO</a>) is gaining investors&#39; confidence due to its impressive partnerships. Of late, the company has launched a slew of products to enhance its portfolio. However, declining COVID-19 testing-related demand, as well as adverse macroeconomic impacts might deter Thermo Fisher&#39;s growth.&nbsp;
Year to date, this Zacks Rank #3 (Hold) company&#39;s shares have rallied 15.7% compared with 7.8% growth of the industry. The S&amp;P 500 composite has risen 17.6% during the said time frame.
The renowned medical and laboratory equipment provider has a market capitalization of $234.75 billion. TMO has had an impressive 14.3% improvement over the past five years, outperforming the industry&#39;s 10.2% growth.
The company&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.98%.
Let&#39;s delve deeper.
<h3>Upsides</h3>
New Partnerships Expand Business:&nbsp;Thermo Fisher continues to expand business banking on strategic alliances. During the second quarter, the company advanced its partnerships in the Asia Pacific region. These included one with the National Battery Research Institute in Indonesia to advance battery technology and energy storage, and another with the Mandaya Hospital Group in Indonesia to help advance stem cell research and cell therapy development.
Thermo Fisher also expanded its partnership in Singapore with the National University Hospital. In March this year, the company collaborated with Bayer AG to develop next-generation sequencing-based companion diagnostic assays (CDx).
Impressive Product Launch:&nbsp;In May 2024, Thermo Fisher Scientific One Lambda Laboratories introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing. In April 2024, TMO unveiled its new metrology solution &mdash; the Thermo Scientific LInspector Edge In-line Mass Profilometer &mdash; to address the needs of the rapidly growing battery market.
During the American Society for Mass Spectrometry Conference in the second quarter of 2024, the company introduced the Thermo Scientific Stellar Mass Spectrometer, which extends Thermo Fisher&#39;s leadership in proteomics.&nbsp;Additionally, the company launched three new build-for-purpose editions of the Thermo Scientific Orbitrap Ascend Tribrid Mass Spectrometer.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b2/74859.jpg?v=1024553431" />
Image Source: Zacks Investment Research
Within the bioproduction business, the company launched a first-of-its-kind bio-based film for single-use technologies. These new bioprocess containers use plant-based materials in place of fossil fuel to provide lower carbon solutions for the manufacturer of biologics. TMO also launched a new line of Thermo Scientific TSX universal series ULT freezers. In recent years, the company has gradually ramped up its R&amp;D investments.
<h3>Downsides</h3>
Macroeconomic Challenges Continue to Weigh on the Stock:&nbsp;The challenging macroeconomic scenario and slower economic recovery in China continue to hurt Thermo Fisher&#39;s growth. The company has been witnessing headwinds in the government and academic markets. Moreover, many countries in Europe are also going through a tough time that might negatively impact their academic budgets. Thermo Fisher remains cautious since its growth could further moderate if the economic scenario worsens.
Lower COVID-19 Sales Hurt Growth:&nbsp;During the COVID-19 pandemic, TMO&#39;s biosciences and bioproduction businesses expanded their capacity to meet the global vaccine manufacturing requirements of pharma and biotech customers. However, in recent quarters, the demand for COVID-19 testing declined, leading to a low-single-digit drop in diagnostics and healthcare revenues.
<h3>Estimate Trend</h3>
The Zacks Consensus Estimate for 2024 earnings per share has moved north 0.4% to $21.72 in the past 30 days.
The Zacks Consensus Estimate for the company&#39;s 2024 revenues is pegged at $42.87 billion, suggesting a 0.02% rise from the year-ago reported number.
<h3>Key Picks</h3>
Some better-ranked stocks in the broader medical space are&nbsp;TransMedix Group,&nbsp;Boston Scientific&nbsp;and&nbsp;Intuitive Surgical.
TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. The company&#39;s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Its shares have soared 153.2% compared with the industry&#39;s 12.6% growth in the past year.
TMDX sports a Zacks Rank #1 (Strong Buy) at present.
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated earnings growth rate of 17.1% compared with the industry&#39;s 15.7%. Shares of the company have rallied 55.7% compared with the industry&#39;s 11.4% growth over the past year.
BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Intuitive Surgical, carrying a Zacks Rank #1 at present, has an estimated long-term earnings growth rate of 17.4% compared with the industry&#39;s 13.7%. Shares of the company have soared 68.3% compared with the industry&#39;s 12.6% growth over the past year.
ISRG&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.
<a href="https://www.zacks.com/stock/news/2325050/reasons-to-retain-thermo-fisher-tmo-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2325050">To read this article on Zacks.com click here.</a>

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 17.5% since its last report. The company recently reported that it has 3.58 million shares sold short, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723561212_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 5.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Thermo Fisher Scientific's Recent Short Interest

The family of Henrietta Lacks has filed a federal lawsuit in Maryland against Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and Viatris Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), alleging the companies profited unlawfully from the use of her tissue cells, known as &#8220;HeLa&#8221; cells.
The Lacks estate claims these cells, which were taken without her knowledge in the 1950s, have been crucial to the companies&#8217; drug developments without any compensation or permission granted to her estate.
Ben Crump, the Lacks family attorney, emphasized the historical exploitation of Black individuals in medical research, highlighting Lacks&#8217; story as a stark example.
The lawsuit follows previous actions against Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), which has since been settled, and ongoing litigation against Ultragenyx Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>).
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38968851/ultragenyx-faces-lawsuit-over-alleged-unjust-use-of-henrietta-lacks-cells" rel="noreferrer noopener">Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks&#8217; Cells</a>.
Henrietta Lacks&#8217;s cells were taken from her cervix during cancer treatment in 1951 at a Baltimore hospital.
Reuters noted that these HeLa cells were the first to survive and reproduce indefinitely in lab conditions. Lacks passed away from cervical cancer later that year at the age of 31.
The complaint details how Novartis allegedly used HeLa cells in the development of its herpes drug Famvir, cancer treatment Kymriah, and spinal muscular atrophy therapy Zolgensma.
Viatris is accused of using these cells to test its herpes drug, Denavir, and depression treatment, Mylan-Mirtazapine.
The Lacks family seeks profits from the commercialization of HeLa cells and a court order to prevent further use without permission.
Price Action: At the last check on Tuesday, NVS stock was up 0.36% at $110.25, and VTRS stock was down 0.30% at $11.53.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40168977/bristol-myers-squibb-terminates-cancer-drug-development-program-with-agenus" target="_blank" rel="noreferrer noopener">Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus</a>.</li>
</ul>
Photo via Shutterstock

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 7.25% on an annualized basis producing an average annual return of 18.78%. Currently, Thermo Fisher Scientific has a market capitalization of $231.45 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 15 years ago, it would be worth $13,586.15 today based on a price of $606.35 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722952825_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 15 Years

Investors with a lot of money to spend have taken a bullish stance on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TMO, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Thermo Fisher Scientific.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $169,740, and 8, calls, for a total amount of $463,297.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $550.0 and $670.0 for Thermo Fisher Scientific, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Thermo Fisher Scientific's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Thermo Fisher Scientific's whale trades within a strike price range from $550.0 to $670.0 in the last 30 days. 
<h3>Thermo Fisher Scientific 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722439858_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.8</td>
<td>$20.7</td>
<td>$20.7</td>
<td>$550.00</td>
<td>$169.7K</td>
<td style="text-align: right;">154</td>
<td style="text-align: right;">86</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$90.1</td>
<td>$86.0</td>
<td>$87.6</td>
<td>$550.00</td>
<td>$105.1K</td>
<td style="text-align: right;">169</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$40.6</td>
<td>$38.1</td>
<td>$40.5</td>
<td>$670.00</td>
<td>$76.9K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">31</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$43.8</td>
<td>$38.8</td>
<td>$40.0</td>
<td>$670.00</td>
<td>$72.0K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">49</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$43.7</td>
<td>$39.3</td>
<td>$39.6</td>
<td>$670.00</td>
<td>$59.4K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">69</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Present Market Standing of Thermo Fisher Scientific</h3>
<ul>
<li>With a volume of 420,187, the price of TMO is down 0.0% at $615.06. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
<h3>What Analysts Are Saying About Thermo Fisher Scientific</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $633.0.
<ul>
<li>Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Thermo Fisher Scientific, targeting a price of $658. </li>
<li>An analyst from Stifel has decided to maintain their Buy rating on Thermo Fisher Scientific, which currently sits at a price target of $615. </li>
<li>An analyst from Raymond James has decided to maintain their Outperform rating on Thermo Fisher Scientific, which currently sits at a price target of $660. </li>
<li>Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $600. </li>
<li>An analyst from Baird persists with their Outperform rating on Thermo Fisher Scientific, maintaining a target price of $632. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Thermo Fisher Scientific with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Check Out What Whales Are Doing With TMO

Joseph R Holmes, VP &amp; Chief Accounting Officer at Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), reported a large exercise of company stock options on July 29, according to a new SEC filing.
What Happened: Holmes, VP &amp; Chief Accounting Officer at Thermo Fisher Scientific, exercised stock options for 860 shares of TMO stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000097745/000112760224021121//Archives/edgar/data/97745/000112760224021121/0001127602-24-021121-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The exercise price of the options was $230.07 per share.
Thermo Fisher Scientific shares are currently trading down by 0.0%, with a current price of $604.12 as of Tuesday morning. This brings the total value of Holmes's 860 shares to $324,027.
<h3>All You Need to Know About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Financial Milestones: Thermo Fisher Scientific's Journey</h3>
Revenue Growth: Over the 3 months period, Thermo Fisher Scientific showcased positive performance, achieving a revenue growth rate of 1.89% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 42.07%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 4.05, Thermo Fisher Scientific showcases strong earnings per share.
</li>
</ul>
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.75, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 37.48 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 5.5 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 22.09, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000097745">Check Out The Full List Of Thermo Fisher Scientific's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Joseph R Holmes At Thermo Fisher Scientific Decides to Exercises Options Worth $324K

These eleven large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares escalated 33.37% after the company announced <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">a private placement financing</a>.</li>
<li>Avantor Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) stock gained 21.62% in the last week after it was announced the stock will join the S&amp;P MidCap 400. Also, it reported better-than-expected Q2 earnings.</li>
<li>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stock jumped 17.73% after the company reported better-than-expected&nbsp;Q2&nbsp;earnings and <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">increased FY 2024&nbsp;guidance</a>.</li>
<li>Manhattan Associates Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) stock upped 17.02% after reporting better-than-expected Q2 financial results. Several analysts raised their <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
<li>Molina Healthcare Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares increased 15.53% following <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">better-than-expected&nbsp;Q2&nbsp;earnings</a>.</li>
<li>First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) shares increased 15.15% after the company reported better-than-expected earnings.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock increased 13.02% after the company reported better-than-expected&nbsp;Q2&nbsp;financial results, and the company raised its FY24&nbsp;guidance&nbsp;above estimates and issued&nbsp;Q3&nbsp;guidance&nbsp;above estimates. Also, the company announced it a<a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">uthorized a&nbsp;$1.5 billion&nbsp;share buyback</a>.</li>
<li>CBRE Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) shares gained 12.99% in the last week after the company raised its 2024 guidance. Several analysts raised their <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecasts on </a><a href="https://www.benzinga.com/quote/CBRE/analyst-ratings" target="_blank" rel="noreferrer noopener">t</a><a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">he stock</a>.</li>
<li>Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) stock rose 12.63% in the last week. The company raised <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">its annual outlook</a>.</li>
<li>Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) stock gained 11.30% are trading higher after the company reported better-than-expected Q2 earnings.</li>
<li>Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) stock grew 10.72% on positive analyst <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">ratings and strong Q2 results</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/07/40001668/ford-stellantis-and-dell-are-among-top-12-large-cap-losers-last-week-july-21-july-27-are-the-other">Ford, Stellantis And Dell Are Among Top 12 Large Cap Losers Last Week (July 21-July 27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Universal Health Services & Lockheed Martin Were Among Top 11 Large Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 20 years by 8.93% on an annualized basis producing an average annual return of 17.23%. Currently, Thermo Fisher Scientific has a market capitalization of $232.09 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 20 years ago, it would be worth $2,362.14 today based on a price of $608.01 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722007820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today

TD Cowen analyst Dan Brennan maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and raises the price target from $648 to $658.

TD Cowen Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $658

J.P. Morgan analyst Rachel Vatnsdal reiterated a Buy rating on Thermo Fisher (TMO – Research Report) today and set a price target of $650.00. Rache...

Buy Rating on Thermo Fisher: Strong Growth and Strategic Positioning Despite Market Uncertainties

Bank of America Securities analyst Michael Ryskin has reiterated their bullish stance on TMO stock, giving a Buy rating today. Michael Ryskin has g...

Thermo Fisher Scientific: A Strong Buy Amid Market Stabilization and Positive Growth Prospects

Since 2020, momentum investing has generated significantly better returns than other strategies. Such is not surprising, given the massive amounts of stimulus injected into the financial system.

Momentum Investing Gives You An Edge, Until It Doesn't

GE HealthCare: The Image Of More Upside Is Very Real

Thermo Fisher (TMO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Daniel Brennan from...

Thermo Fisher's Market Dominance and Growth Prospects Bolster Buy Rating

Thermo Fisher (TMO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brandon Couillard f...

Buy Rating Affirmed for Thermo Fisher on Strong Growth and Strategic Execution

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Thermo Fisher (TMO – Research Report), Nyxoah (NYXH ...

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Nyxoah (NYXH) and Assembly Biosciences (ASMB)

In a report released today, Conor McNamara from RBC Capital maintained a Buy rating on Thermo Fisher (TMO – Research Report), with a price target o...

RBC Capital Remains a Buy on Thermo Fisher (TMO)

In a report released yesterday, Tycho Peterson from Jefferies maintained a Buy rating on Thermo Fisher (TMO – Research Report), with a price target...

Thermo Fisher: A Buy Rating Based on Strong Growth Prospects and Strategic Market Positioning

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merit Medical Systems (MMSI – Research Report) and T...

Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI) and Thermo Fisher (TMO)

ASMB

COST

GEHC

MMSI

MRNA

MSFT

MTUM

NVDA

NYXH

SEMHF

SMMNY

Press Releases

Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

Thermo Fisher Scientific Declares Quarterly Dividend

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

Thermo Fisher Scientific Reports Second Quarter 2024 Results

Small Cap

Opinion

Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth

Thermo Fisher Scientific to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024

Thermo Fisher Scientific Hosts 2024 Investor Day

BVAXF

CSE:BIOV

NEOG

RHHBY

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Thermo Fisher Scientific

Thermo Fisher Scientific (TMO) Forecast

Thermo Fisher Scientific (NYSE:TMO) Stock, Quote.Headers.trade-ideas